Company Profile

Activoris is the German medical device specialist, building up on decades of management experience in the medtech and pharma industry. Learn about our competences…


Our Services

Learn more about our services around manufacturing, clinical trial supply, device developments and strategic support…

Latest News

February 27, 2018 – Activoris obtains Manufacturing License for Clinical Trial Material: Activoris expands its packaging services towards drugs for clinical trials. (full press release)

November 14, 2017 – 1.3 Million Investment in Nightly Nasal Aerosol Therapy: Thora Tech and Activoris to team-up with University Clinics Marburg and Löwenstein Medical Technology for the development of a system for nightly aerosol therapy for patients with chronic lung diseases. (full press release)

October 10, 2017 – nice!Innovation’s „snakeFX“ achieves convincing test results – External fixator shows superior usability characteristics: Activoris’ customer nice!Innovations GmbH today announced the top line results of the first usability studies with their innovative external fixator „snakeFX“. The response is encouraging: surgeons like stability, user comfort and the chance for a fast fixation in emergencies with snakeFX. (full press release)

June 19, 2017 – Activoris and AJW Technology Consultants, Inc. form strategic partnership
Both companies today announced a strategic partnership for international development and regulatory support (full press release).

June 16, 2017 – Activoris strengthens Management Team with experienced Pharma Executive
Activoris Medizintechnik GmbH today announced that Dr. Thomas Julien will take-over responsibility for production and logistics with immediate effect (full press release).

April 07, 2017 – Activoris supported feelSpace GmbH for capital increase
Germany based feelSpace GmbH, a specialist in tactile navigation systems for the blind and visually impaired, today announced the closing of a 600,000 € financing round. Activoris assisted feelSpace during fund raising and closing (full press release).